Zymeworks Inc. (ZA8)

Overview

Zymeworks Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of novel biotherapeutics for the treatment of cancer. Established in 2003 and headquartered in Vancouver, Canada, the company leverages its expertise in the field to develop cutting-edge treatments aimed at improving patient outcomes. Zymeworks Inc. has established a strong network of strategic partnerships with leading pharmaceutical and biotechnology companies, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Moreover, Zymeworks maintains licensing and research collaborations with LEO Pharma A/S and Iconic Therapeutics, Inc., focusing on the research, development, and commercialization of bispecific antibodies. These partnerships and collaborations underpin the company's efforts to bring innovative cancer treatments from the laboratory to the clinic.

Products and Services

• Zanidatamab

A novel bispecific antibody, zanidatamab is at the forefront of Zymeworks Inc.'s pipeline, currently undergoing Phase 1 and Phase 2 clinical trials. This innovative therapy is designed to target biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer. Through its dual-targeting mechanism, zanidatamab aims to provide a new therapeutic option for patients battling these forms of cancer, offering hope for improved treatment outcomes.

• ZW49

ZW49 represents Zymeworks Inc.'s advancement in the targeted treatment of HER2-expressing tumors. This biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate is currently in Phase 1 clinical trial, focusing on patients with advanced or metastatic HER2-expressing tumors. By combining targeted therapy with a potent cytotoxic drug, ZW49 has the potential to effectively kill cancer cells while minimizing harm to normal tissues, thus presenting a promising therapeutic approach for individuals with HER2-positive cancers.